Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PEG-IFN alfa-2a, Tenofovir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PEG-IFN alfa-2a plus placebo | PLACEBO_COMPARATOR | Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally |
| PEG-IFN alfa-2a plus Tenofovir | ACTIVE_COMPARATOR | Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally |
| Name | Type | Description |
|---|---|---|
| PEG-IFN alfa-2a, Tenofovir | DRUG | Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally |
| PEG-IFN alfa-2a, placebo | DRUG | Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally |
Inclusion Criteria: * Written informed consent. * Age \> 18 years. * Positive HBsAg, for at least the prior 6 months, positive anti-HDV for at least 3 months and positive for HDV-RNA by PCR within the screening period. * Elevated serum ALT ≥ ULN but ≤ 10X ULN as determined by two abnormal values ta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | MIRM | 4 | PHASE3 | Brelovitug, Delayed Treatment with Brelovitug |
| Vir Biotechnology, Inc. | VIR | 1 | PHASE2 | VIR-2218, VIR-3434, NRTI |
| Gilead Sciences, Inc. | GILD | 2 | PHASE1 | GS-4321 |
PEG-IFN alfa-2a, Tenofovir is used for the treatment of Hepatitis D, a chronic viral infection of the liver. It is being studied as a combination therapy to evaluate its efficacy and safety in patients with this condition.
PEG-IFN alfa-2a, Tenofovir is developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD.
PEG-IFN alfa-2a, Tenofovir is in Phase 2 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities for the treatment of Hepatitis D.
PEG-IFN alfa-2a, Tenofovir has been studied in one completed Phase 2 clinical trial, identified as NCT00932971, titled 'HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis'. This trial enrolled 70 participants and was conducted in Germany, Greece, and Romania.
Yes, PEG-IFN alfa-2a, Tenofovir is the same as PegIFN-alfa2a plus Tenofovir. The combination therapy is referred to by both names, with the clinical trial NCT00932971 using the latter designation.